High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F19%3A00012736" target="_blank" >RIV/00023736:_____/19:00012736 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.3390/ijms20112823" target="_blank" >https://doi.org/10.3390/ijms20112823</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ijms20112823" target="_blank" >10.3390/ijms20112823</a>

Result language
angličtina
Original language name
High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations
Original language description
We analyzed PD-L1 expression on AML primary cells by flow cytometry and, in parallel, transcript levels were determined for the transcription variants v1 and v2. The ratio of v1/v2 cDNA correlated with the surface protein amount, and high v1/v2 levels were associated with worse overall survival (p = 0.0045). The prognostic impact of PD-L1 was limited to AML with mutated nucleophosmin and concomitant internal tandem duplications in the FLT3 gene (p less than 0.0001 for this particular AML subgroup).
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/NV16-30268A" target="_blank" >NV16-30268A: Mutated nucleophosmin as a potential target for immunotherapy of acute myelogenous leukemia</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)